To determine the safety & immunogenicity of a potential vaccine against meningococcal B disease
Official Title
A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults
Conditions
Meningitis, Meningococcal
Study Type
Interventional
Study Design
Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study
Further Details
Primary Outcome Measures:
- Local & systemic safety throughout the trial
Secondary Outcome Measures:
- Evidence of an immune response 1 month after dose 2 & 1 month after dose 3
Study Start
March 2006
Eligibility & Criteria
- Ages Eligible for Study: 18 Years – 25 Years
- Genders Eligible for Study: Both
- Accepts Healthy Volunteers
Inclusion Criteria:
- Healthy 18-25 year olds
Exclusion Criteria:
- Prior history of vaccination with any meningococcal vaccine
- Prior history of any invasive meningococcal disease
Total Enrolment
108
Contact Details
- Herson, Queensland, 4006, Australia
- North Adealaide, South Australia, 5006, Australia
- Perth, Western Australia, 6840, Australia
For more information, click here
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.
Related Articles
Need a health appointment?
Find and book a doctor, dentist, physio and more on Healthengine
Find a practitioner
